Product How it works Pricing Blog FAQ About Contact
Cartesian Therapeutics

Cartesian Therapeutics (NASDAQ: RNAC) revenue

Cartesian Therapeutics reported revenue of $2.8m for fiscal 2025, 92.8% less than in fiscal 2024 ($38.9m). Since fiscal 2016 its revenue has fallen by 65.4%, an average decline of 11.1% a year.

Cartesian Therapeutics's best year of the last 10 was fiscal 2022. The biggest drop was in fiscal 2017, −97.4%.

Revenue, in millions of US dollars8.120160.220170.920186.7201916.6202085.12021110.8202226.0202338.920242.82025
Embed this chart

Copy this code into your website or blog. The chart updates with each new annual report.

Revenue by fiscal year

Fiscal yearRevenueChangeOperating profitOperating margin
2025$2.8m−92.8%−$143.4m−5,127.1%
2024$38.9m+49.6%−$43.9m−112.8%
2023$26.0m−76.5%−$86.4m−332.3%
2022$110.8m+30.2%$14.5m13.1%
2021$85.1m+412.6%−$4.6m−5.4%
2020$16.6m+148.6%−$56.8m−342.4%
2019$6.7m+639.4%−$52.5m−785.6%
2018$0.9m+336.2%−$65.0m−7,200.7%
2017$0.2m−97.4%−$63.8m−30,813.5%
2016$8.1m—−$34.7m−428.9%

The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.

Cartesian Therapeutics revenue compared with its sector

By revenue for its latest fiscal year, Cartesian Therapeutics ranks 391st of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Cartesian Therapeutics, −92.8%.

RankCompanyRevenueRevenue growth
389thUpstream Bio$2.9m20.4%
390thAbsci$2.8m−38.2%
391stCartesian Therapeutics$2.8m−92.8%
392ndAllogene Therapeutics$2.6m2,500.0%
393rdOramed Pharmaceuticals$2.0m—

Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.

Questions about the revenue of Cartesian Therapeutics

How much revenue did Cartesian Therapeutics make in fiscal 2025?
Cartesian Therapeutics reported revenue of $2.8m for fiscal 2025, compared with $38.9m in fiscal 2024.
How much has the revenue of Cartesian Therapeutics fallen?
Between fiscal 2016 and fiscal 2025 it went from $8.1m to $2.8m: 65.4% less, an average decline of 11.1% a year.
What was the best year for revenue at Cartesian Therapeutics?
Of its last 10 fiscal years, fiscal 2022, with $110.8m.
Where does Cartesian Therapeutics rank in its sector by revenue?
It ranks 391st of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
Where do the figures for Cartesian Therapeutics come from?
From the annual report (Form 10-K) that Cartesian Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.

Where each figure comes from

From the annual report (Form 10-K) that Cartesian Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017 · 2016. More on Cartesian Therapeutics: the Cartesian Therapeutics page · annual accounts · net income · insider transactions.

Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.